Read by QxMD icon Read

leukemia AND treatment

Ying-Ju Lai, Wan-Nien Yu, Sheng-Chu Kuo, Chi-Tang Ho, Chao-Ming Hung, Tzong-Der Way, Chiung-Tong Chen
Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancer deaths worldwide, especially in male. With poor prognosis, significant portions of patients with HNSCC die due to cancer recurrence and tumor metastasis after chemotherapy and targeted therapies. The HNSCC FaDu cell ectopic expression of Twist, a key transcriptional factor of epithelial-mesenchymal transition (EMT), which triggers EMT and results in the acquisition of a mesenchymal phenotype, was used as the cell model. Our results demonstrated that treatment with newly synthesized 2-(3-hydroxyphenyl)-5-methylnaphthyridin-4-one (CSC-3436), a flavonoid derivative, elicited changes in its cell morphology, upregulated E-cadherin messenger RNA and protein expression, downregulated N-cadherin, vimentin, and CD133 (a marker associated with tumor-initiating cells) in FaDu-pCDH-Twist cells...
October 20, 2018: Journal of Cellular Physiology
Nobuhiko Nakamura, Soranobu Ninomiya, Takuro Matsumoto, Hiroshi Nakamura, Junichi Kitagawa, Makoto Shiraki, Takeshi Hara, Masahito Shimizu, Hisashi Tsurumi
Skeletal muscle atrophy and loss of adipose tissue, referred to as sarcopenia and adipopenia, respectively, are often observed in cancer patients. We investigated the impact of sarcopenia and adipopenia on clinical outcomes in 90 adult patients with newly diagnosed acute myeloid leukemia (AML) who received induction chemotherapy. Computed tomography (CT) before treatment revealed sarcopenia in 39 patients (43%) and adipopenia in 35 patients (39%). We analyzed the treatment efficacy of induction chemotherapy and survival outcomes...
October 19, 2018: Annals of Hematology
Celine-Marie Pascale, Catherine M Schaeff
OBJECTIVES: This pilot case study sought to examine the efficacy of subtle energy treatments as conducted by Buddhist healing master Segyu Rinpoche at his Juniper Integrative Clinic in Northern California. DESIGN: Over the course of a year, this study followed two patients with terminal diagnoses, their treating physicians, and Segyu Rinpoche as the patients underwent treatment at the Juniper Clinic. The patients entering the study had exhausted all known medical options...
August 21, 2018: Explore: the Journal of Science and Healing
P Chastagner, D Michel, A Contet, A Lozniewski, T Hadou, C Schmitt, A Phulpin, F Fouyssac, L Mansuy
BACKGROUND: Infection is the major cause of treatment-related mortality in childhood acute leukemia, mainly due to bacterial translocation across the intestinal mucosa. Only a few studies have reported the impact of different antibacterial prophylaxis treatments on digestive tract flora and infection-related mortality. PROCEDURES: We performed a retrospective analysis of two different digestive tract decontamination modalities (selective or total digestive decontamination) in a large single-center series of 323 children during the induction treatment of acute leukemia between January 1995 and December 2014...
October 16, 2018: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John Powers, Lisa Nodzon, Fadi Kayali, Kelly Hyland, Ashley Nelson, Javier Pinilla-Ibarz
PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases TKI-induced apoptosis. A phase I clinical trial (NCT01702064) investigated the tolerability and safety of treating chronic-phase chronic myeloid leukemia patients with ruxolitinib in combination with the BCR-ABL TKI nilotinib and explored initial efficacy evidence...
October 9, 2018: Leukemia Research
Jose L Lepe-Zuniga, Virginia Ramirez-Nova
Childhood Lymphoblastic leukemia's (ALL) early mortality (EM) is an undesirable treatment outcome for a disease for which >90% long term success is achievable. In the Western world EM constitutes no >3%; yet, in Chiapas, Mexico, remains around 15%. With the objective of improving on EM, we determined associated elements in 28 ALL who died within 60 days of arriving at Hospital de Especialidades Pediátricas in Chiapas (HEP), by comparing them to those in 84 controls who lived beyond the first 90 days...
October 18, 2018: Journal of Pediatric Hematology/oncology
Ji-Young Seok, Yun-Jeong Jeong, Soon-Kyung Hwang, Cheorl-Ho Kim, Junji Magae, Young-Chae Chang
4-O-methylascochlorin (MAC) is a derivative of ascochlorin, a prenyl-phenol compound antibiotic isolated from the fungus Ascochyta viciae. MAC induces caspase/poly (ADP-ribose) polymerase-mediated apoptosis in leukemia cells. However, the effects of MAC on autophagy in cancer cells and the underlying molecular mechanisms remain unknown. Here, we show that MAC induces autophagy in lung cancer cells. MAC significantly induced the expression of autophagy marker proteins including LC3-II, Beclin1, and ATG7. MAC promoted AMP-activated protein kinase (AMPK) phosphorylation and inhibited the phosphorylation of mammalian target of rapamycin (mTOR) and its downstream signalling proteins P70S6K and 4EBP1...
October 19, 2018: Journal of Cellular and Molecular Medicine
D-M Liu, X-D Zhang, L Yang
OBJECTIVE: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), as standing out for its distinguished sensitivity to all-trans retinoic acid and arsenic trioxide (ATO, As2O3). The As2O3-mediated degradation of PML-RARA (promyelocytic leukemia-retinoic acid receptor-α) oncoprotein via the proteasome pathway appears to be critical for such distinguished sensitivity. MATERIALS AND METHODS: The present study was to evaluate the influence by chloroquine (CQ), an inhibitor to the release of lysosomal enzymes, on the sensitivity of APL cells to As2O3...
October 2018: European Review for Medical and Pharmacological Sciences
P Muggeo, E Calore, N Decembrino, S Frenos, F De Leonardis, A Colombini, F Petruzziello, K Perruccio, M Berger, R Burnelli, G A Zanazzo, N Santoro, S Cesaro
BACKGROUND: Invasive mucormycosis is a rare but frequently fatal fungal disease. The acute and rapidly progressive evolution causes unfavourable outcome in 22-59% of patients and its treatment represents a clinical challenge, especially in immunocompromised patients. Current data in pediatric oncological patients are limited. OBJECTIVES: The infection Working Group of the Italian Association of Pediatric Hematology and Oncology (AIEOP) analyzed the episodes of invasive mucormycosis occurred between 2009 and 2016...
October 18, 2018: Mycoses
Nicole Weiler, Erick F Mayer, Viktoryia Kazlouskaya, Oluwatoyin F Bamgbola, Natalie Banniettis, Edward Heilman, Sharon A Glick
Infective dermatitis (ID) associated with Human T-cell leukemia virus type-1 (HTLV-1) is a rare form of severe superinfected eczema seen mostly in the Caribbean islands and Latin America. Although rapid response to antibiotic treatment is observed, patients should be monitored for development of complications associated with this retroviral infection, including T-cell leukemia/lymphoma (ATLL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Infective dermatitis is rarely seen in the United States and therefore may be under-recognized by physicians unfamiliar with this condition...
October 18, 2018: Pediatric Dermatology
Lata Rani, Ajay Gogia, Vishwajeet Singh, Lalit Kumar, Atul Sharma, Gurvinder Kaur, Ritu Gupta
Prognostic indices combining several clinical and laboratory parameters have been proposed for prognostication in chronic lymphocytic leukemia (CLL). Recently, international consortium on CLL proposed an international prognostic index (CLL-IPI) integrating clinical, molecular, and genetic parameters. The present study was designed to evaluate the reproducibility of CLL-IPI in Indian CLL cohort. The prognostic ability of CLL-IPI in terms of overall survival (OS) and time to first treatment (TTFT) was investigated in treatment-naive CLL patients and also compared with other existing prognostic scores...
October 18, 2018: Annals of Hematology
Hangsak Huy, Tae-Don Kim, Won Sam Kim, Dong Oh Kim, Jae-Eun Byun, Mi Jeong Kim, Young-Jun Park, Suk Ran Yoon, Ji-Yoon Noh, Jungwoon Lee, Kyoo-Hyung Lee, Inpyo Choi, Haiyoung Jung
Overcoming drug resistance is one of key issues in treating refractory acute myeloid leukemia (AML). The Toll-like receptor 4 (TLR4) signaling pathway is involved in many aspects of biological functions of AML cells, including the regulation of pro-inflammatory cytokine products, myeloid differentiation, and survival of AML cells. Thus, targeting TLR4 of AML patients for therapeutic purposes should be carefully addressed. In this regard, we investigated the possible role of TLR4 as a regulatory factor against fludarabine (FA) cytotoxicity activity...
October 15, 2018: Biochemical and Biophysical Research Communications
Eman Mosaad Zaki, Asmaa Mohamed Zahran, Alshimaa Abdelazeem Metwaly, Rania Hafez, Safinaz Hussein, Abdallah Elaiw Mohammed
OBJECTIVE/BACKGROUND: Chronic lymphocytic leukemia is one of the commonest leukemias affecting adults. CD39 inhibits T-cell and NK cell responses by hydrolyzing adenosine triphosphate and adenosine diphosphate, suppressing the immune system. We investigated expression of CD39 on CD4+ T Lymphocytes in chronic lymphocytic leukemia (CLL) patients and its relationship with deletion 6q, its association with disease stage and survival. METHODS: Thirty CLL patients and 20 matched controls were included in the study...
October 11, 2018: Hematology/oncology and Stem Cell Therapy
Yefei Shu, Wei Yang, Xuejin Zhang, Xiaofeng Xu
RATIONALE: Variant Philadelphia chromosome translocations involving chromosomes other than chromosomes 9 and 22 have been reported in 5% to 10% of patients with chronic myeloid leukemia (CML). Here, a case of CML with a t (9, 22, 16) (q34; q11; p13) translocation, which has never been described, is reported. PATIENT CONCERNS: A 59-year-old female with dry cough, referred to our hospital, exhibited hepatosplenomegaly, high basophil count, and high platelet count at admission without any other known chronic diseases...
October 2018: Medicine (Baltimore)
Krisztián Kállay, Judit Csomor, Emma Ádám, Csaba Bödör, Csaba Kassa, Réka Simon, Gábor Kovács, György Péter, Gábor Ottóffy, Katalin Bartyik, Csongor Kiss, Péter Masát, Marienn Réti, Blanka Tóth, Gergely Kriván
INTRODUCTION: Acquired bone marrow failures are rare but fatal diseases in childhood. Since 2013, Hungary has been participating as a full member in the work of the European Working Group on uniform diagnostics and therapy in patients with acquired bone marrow failure syndromes. Hypocellular refractory cytopenia of childhood has been emphasized as a frequent entity, transplanted by reduced intensity conditioning with excellent outcomes. AIM: To analyse and compare the results of treatment before and after our joining...
October 2018: Orvosi Hetilap
Ramy Rahmé, Lionel Adès
Myelodysplastic syndromes (MDS) are clonal stem cell disorders mostly affecting the elderly. They are classified into lower and higher risk MDS according to prognostic scoring systems. In higher-risk patients, treatments should aim to modify the disease course by avoiding progression to acute myeloid leukemia, and therefore to improve survival. Areas covered: Stem cell transplantation remains the only curative treatment when feasible, but this concerns a small minority of patients. Treatment is principally based on hypomethylating agents (HMAs)...
October 18, 2018: Expert Review of Hematology
K Polakova, E Bandzuchova
HLA-G antigens and matrix metalloproteinases (MMPs) expressed in various tumors are involved in tumor growth and metastasis. In this study we investigated whether in cell lines of different origin exist some correlation between HLA-G and MMP expression. First, we examined MMP transcription in two choriocarcinoma cell lines: JEG-3 (HLA-G positive) and JAR (HLA-G negative). We discovered that both cell lines express similar panel of MMPs except MMP12. Transcript MMP12 was exclusively detected in HLA-G expressing JEG-3 cells but not in HLA-G deficient JAR cells...
September 4, 2018: Neoplasma
Shefaa AlAsfoor, Theresa V Rohm, Angela J T Bosch, Thomas Dervos, Diego Calabrese, Matthias S Matter, Achim Weber, Claudia Cavelti-Weder
Macrophages have been recognized as key players in non-alcoholic fatty liver disease (NAFLD). Our aim was to assess whether pharmacological attenuation of macrophages can be achieved by imatinib, an anti-leukemia drug with known anti-inflammatory and anti-diabetic properties, and how this impacts on NAFLD. We analyzed the pro- and anti-inflammatory gene expression of murine macrophages and human monocytes in vitro in the presence or absence of imatinib. In a time-resolved study, we characterized metabolic disease manifestations such as hepatic steatosis, systemic and adipose tissue inflammation as well as lipid and glucose metabolism in obese mice at one and three months of imatinib treatment...
October 17, 2018: Scientific Reports
Vivek Kumar Singh, Mohane Selvaraj Coumar
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused due to translocation between chromosome 9 and 22 leading to chimeric gene product known as Bcr-Abl. Bcr-Abl fusion protein has constitutively activated Abl tyrosine kinase activity which is responsible for the uncontrolled proliferation in CML The tyrosine kinase inhibitors (TKIs) such as Imatinib, Dasatinib, and Nilotinib are the current firstline treatments approved by the United States Food and Drug Administration (US FDA) for the treatment of the disease...
October 17, 2018: Mini Reviews in Medicinal Chemistry
Dilana Staudt, Heather C Murray, Tabitha McLachlan, Frank Alvaro, Anoop K Enjeti, Nicole M Verrills, Matthew D Dun
The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML). The receptor tyrosine kinase FLT3 is the most commonly mutated gene in AML, with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) or missense mutations in the tyrosine kinase domain (FLT3-TKD) present in 30⁻35% of AML patients at diagnosis...
October 16, 2018: International Journal of Molecular Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"